Westfield Capital Management Co. LP Has $153.06 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Westfield Capital Management Co. LP grew its holdings in Insulet Co. (NASDAQ:PODD) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 705,429 shares of the medical instruments supplier’s stock after acquiring an additional 68,168 shares during the period. Insulet accounts for approximately 0.9% of Westfield Capital Management Co. LP’s holdings, making the stock its 20th largest position. Westfield Capital Management Co. LP’s holdings in Insulet were worth $153,064,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PODD. Baillie Gifford & Co. bought a new position in Insulet in the 4th quarter worth approximately $263,144,000. Norges Bank acquired a new position in Insulet during the 4th quarter worth about $227,655,000. William Blair Investment Management LLC grew its stake in shares of Insulet by 145.1% during the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock valued at $116,894,000 after purchasing an additional 433,884 shares during the last quarter. Northern Trust Corp boosted its position in Insulet by 7.6% in the 3rd quarter. Northern Trust Corp now owns 681,731 shares of the medical instruments supplier’s stock valued at $108,729,000 after buying an additional 47,938 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Insulet by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 407,592 shares of the medical instruments supplier’s stock valued at $88,439,000 after acquiring an additional 22,247 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have commented on PODD. Jefferies Financial Group upped their target price on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Barclays dropped their target price on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. Raymond James lowered their price target on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a research note on Tuesday, May 7th. Finally, Piper Sandler lowered their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $239.44.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of NASDAQ:PODD traded up $9.28 during trading on Friday, reaching $180.07. 680,298 shares of the stock were exchanged, compared to its average volume of 901,600. The firm has a market cap of $12.61 billion, a PE ratio of 54.57, a PEG ratio of 3.26 and a beta of 1.00. The stock has a 50-day moving average price of $171.74 and a 200-day moving average price of $184.36. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $298.95.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The business’s revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.23 EPS. Research analysts expect that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.